BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27566971)

  • 1. Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma.
    Tsubokawa N; Mimae T; Miyata Y; Sasada S; Yoshiya T; Kushitani K; Takeshima Y; Murakami S; Yokose T; Ito H; Nakayama H; Okada M
    Jpn J Clin Oncol; 2016 Nov; 46(11):1015-1021. PubMed ID: 27566971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
    Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma.
    Hou Y; Song W; Chen M; Zhang J; Luo Q; Um SW; Facchinetti F; Bongiolatti S; Zhou Q
    Transl Lung Cancer Res; 2022 Jan; 11(1):64-74. PubMed ID: 35242628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor histological components predict the recurrence of patients with resected stage I acinar- or papillary-predominant lung adenocarcinoma.
    Liu W; Zhang Q; Zhang T; Li L; Xu C
    Front Oncol; 2022; 12():1090544. PubMed ID: 36620572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor.
    Araki K; Kidokoro Y; Hosoya K; Wakahara M; Matsuoka Y; Takagi Y; Haruki T; Miwa K; Taniguchi Y; Horie S; Nakamura H
    Anticancer Res; 2014 Jun; 34(6):3153-6. PubMed ID: 24922687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma.
    Jeon HW; Kim YD; Sim SB; Moon MH
    Thorac Cancer; 2022 Sep; 13(17):2473-2479. PubMed ID: 35820717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.
    Yoshiya T; Mimae T; Tsutani Y; Tsubokawa N; Sasada S; Miyata Y; Kushitani K; Takeshima Y; Murakami S; Ito H; Nakayama H; Okada M
    Ann Thorac Surg; 2016 Nov; 102(5):1668-1673. PubMed ID: 27344277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.
    Hung JJ; Jeng WJ; Chou TY; Hsu WH; Wu KJ; Huang BS; Wu YC
    Ann Surg; 2013 Dec; 258(6):1079-86. PubMed ID: 23532112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
    Kim M; Chung YS; Kim KA; Shim HS
    Lung Cancer; 2019 Nov; 137():129-135. PubMed ID: 31586770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Effects of Predominant Histologic Subtypes in Resected Pulmonary Adenocarcinomas.
    Yaldız D; Örs Kaya Ş; Ceylan KC; Acar A; Aydoğdu Z; Gürsoy S; Yaldız S
    Balkan Med J; 2019 Oct; 36(6):347-353. PubMed ID: 31525846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
    Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma.
    Sasada S; Nakayama H; Miyata Y; Tsubokawa N; Mimae T; Yoshiya T; Murakami S; Ito H; Okada M
    Ann Thorac Surg; 2015 Mar; 99(3):956-60. PubMed ID: 25620597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
    Zhang H; Sun FH; Chen ZC; Wang Q
    Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiologic findings to predict low-grade malignant tumour among clinical T1bN0 lung adenocarcinomas: lessons from histological subtypes.
    Mimae T; Miyata Y; Mimura T; Ito H; Nakayama H; Okumura S; Yoshimura M; Okada M
    Jpn J Clin Oncol; 2015 Aug; 45(8):767-73. PubMed ID: 26056324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.
    Jeon HW; Kim YD; Sim SB; Moon MH
    Thorac Cancer; 2021 Jul; 12(14):2072-2077. PubMed ID: 34033216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size.
    Takahashi Y; Ishii G; Aokage K; Hishida T; Yoshida J; Nagai K
    Lung Cancer; 2013 Feb; 79(2):118-24. PubMed ID: 23177278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.
    Song Z; Zhu H; Guo Z; Wu W; Sun W; Zhang Y
    Eur J Surg Oncol; 2013 Nov; 39(11):1262-8. PubMed ID: 24063970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of the second predominant subtype in lung adenocarcinoma: a retrospective single-center cohort study.
    Sun S; Li S; Li J; Li X; Ding Y; Liu X; Wang K; Shi Y; Sun D
    J Thorac Dis; 2022 Dec; 14(12):4846-4864. PubMed ID: 36647489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.